Acute Liver Failure: From Mechanistic Insights to Emerging Liver Support Strategies
Nov
10
2025
Convention Center: Room 146B, Level 1
11:00 AM
- 12:30 PM
Description
This session will explore the rapidly evolving landscape of acute liver failure (ALF), addressing both the underlying pathophysiological mechanisms and cutting-edge approaches to liver support. Participants will gain insights into the immunological and metabolic contributors to ALF, including novel findings in pyroptosis and immune cell activation, as well as comorbid factors in drug-induced liver injury. The session will also highlight therapeutic innovations, including bioartificial liver systems, stem cell-derived hepatocyte technologies, and therapeutic plasma exchange. Through clinical trials and translational research, this session aims to bridge the gap between bench and bedside in the management of ALF.Journey Maps
Presentations
11:15 AM
- 11:30 AM
May
18
2026
Washington, D.C.
"More Than Just Drugs: Viral and Metabolic Comorbidities in Drug-Induced Liver Injury"
Deirdre A Kelly, MD, FAASLD
, Abstract Presenter
Acute Liver Failure
12:00 PM
- 12:15 PM
May
18
2026
Washington, D.C.
"First-in-Human Trial of the HepaCure Bioartificial Liver System in Acute-on-Chronic Liver Failure"
William Bernal, MD, FAASLD, FRCP
, Abstract Presenter
Acute Liver Failure
Objectives
- Describe emerging cellular and immune mechanisms involved in acute liver failure, including inflammasome activation, macrophage polarization, and T-cell dysregulation.
- Evaluate the current and future role of artificial and bioartificial liver support systems, including outcomes from recent clinical trials and preclinical studies.
- Recognize the influence of comorbid factors such as viral infections and metabolic dysfunction in drug-induced liver injury and their implications for ALF diagnosis and management.